Welcome to the 8th Neurodegenerative Drug Development Summit
Previously the World CNS Summit
Thank you to our expert speakers and everyone who attended the 2020 summit
The 8th Neurodegenerative Drug Development Summit, previously World CNS, was held in Boston in February 2020.
Despite the lack of clinical trial success, new investments are being made in forward-thinking biotechs, digital and blood-based biomarker technologies are advancing, new targets are emerging, and gene therapy is taking the limelight.
The Neurodegenerative Drug Development Summit united industry stakeholders to learn how to overcome their translational challenges, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics.
This presented an opportunity to join over 150 fellow CNS experts from Biogen, AbbVie, Sanofi and more, and allowing attendees to immerse themselves in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
41 World-Class Speakers Including:
Global Head, External Innovation
University of Gothenburg
Director, Translational Sciences
Vice President, Head Neuroscience & Imaging Research & Early Development
Third Rock Ventures
Senior Director, Neuroscience Innovation
Global Head of Medical Alzheimer’s
Executive Vice President & Head of Research & Development
Chief Scientific Officer
Director, Neuroscience Discovery
Neurodegenerative Drug Development Summit is Proud to Partner With:
“Great meeting that has the right balance of science, drug discovery & development, and networking” - Jonathan Levenson, Senior Director, Proclara BioSciences
|“High level, focused meeting, with overall very interesting presentations and discussion by decision makers in CNS R&D” - Johan Luthman, VP of Clinical Development, Eisai|
|"Outstanding conference" - Richard Wyse, Director of R&D, The Cure Parkinson’s Trust|